HK1246293A1 - 布鲁顿酪氨酸激酶抑制剂的合成 - Google Patents
布鲁顿酪氨酸激酶抑制剂的合成 Download PDFInfo
- Publication number
- HK1246293A1 HK1246293A1 HK18105861.5A HK18105861A HK1246293A1 HK 1246293 A1 HK1246293 A1 HK 1246293A1 HK 18105861 A HK18105861 A HK 18105861A HK 1246293 A1 HK1246293 A1 HK 1246293A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bruton
- synthesis
- tyrosine kinase
- kinase inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103507P | 2015-01-14 | 2015-01-14 | |
| US62/103,507 | 2015-01-14 | ||
| PCT/US2016/013424 WO2016115356A1 (en) | 2015-01-14 | 2016-01-14 | Synthesis of a bruton's tyrosine kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1246293A1 true HK1246293A1 (zh) | 2018-09-07 |
Family
ID=56406389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18105861.5A HK1246293A1 (zh) | 2015-01-14 | 2016-01-14 | 布鲁顿酪氨酸激酶抑制剂的合成 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US20180009814A1 (https=) |
| EP (1) | EP3245208A4 (https=) |
| JP (2) | JP2018502077A (https=) |
| KR (1) | KR20170102887A (https=) |
| CN (2) | CN113816962A (https=) |
| AU (2) | AU2016206693A1 (https=) |
| BR (1) | BR112017015206B1 (https=) |
| CA (2) | CA3210320A1 (https=) |
| HK (1) | HK1246293A1 (https=) |
| IL (4) | IL308276A (https=) |
| MA (1) | MA41350A (https=) |
| MX (2) | MX366827B (https=) |
| RU (1) | RU2017128308A (https=) |
| SG (2) | SG10201906517VA (https=) |
| WO (1) | WO2016115356A1 (https=) |
| ZA (1) | ZA201704338B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10214532B2 (en) * | 2015-02-12 | 2019-02-26 | Shanghai Dude Medical Science and Technology Co., Ltd. | Process for preparing ibrutinib |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| CN109206426B (zh) * | 2017-07-06 | 2021-10-08 | 上海复星星泰医药科技有限公司 | 吡唑并嘧啶类化合物的制备方法 |
| JP7166331B2 (ja) | 2017-08-01 | 2022-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 中間体化合物及び方法 |
| CN107814804A (zh) * | 2017-10-27 | 2018-03-20 | 广州科锐特生物科技有限公司 | 依鲁替尼的制备方法 |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| US20210121466A1 (en) | 2018-05-03 | 2021-04-29 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| JP6944496B2 (ja) * | 2018-10-22 | 2021-10-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体 |
| WO2020095452A1 (ja) | 2018-11-09 | 2020-05-14 | 大鵬薬品工業株式会社 | ジメトキシベンゼン化合物の製造方法 |
| CN109988175A (zh) * | 2019-04-28 | 2019-07-09 | 梯尔希（南京）药物研发有限公司 | 一种依鲁替尼-d5的制备方法 |
| AU2020280904A1 (en) * | 2019-05-21 | 2021-11-18 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a BTK inhibitor |
| AU2020278162A1 (en) | 2019-05-21 | 2021-11-18 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a BTK inhibitor |
| WO2022157250A1 (en) | 2021-01-21 | 2022-07-28 | Synthon B.V. | Process for making ibrutinib |
| CN114853662B (zh) * | 2021-02-05 | 2024-01-12 | 四川青木制药有限公司 | 手性肼基哌啶衍生物的制备方法 |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550214A (en) * | 1981-01-05 | 1985-10-29 | Polaroid Corporation | Blocked vinyl biphenyl compounds |
| US4874822A (en) * | 1988-04-07 | 1989-10-17 | Minnesota Mining And Manufacturing Company | Process for the acrylamidoacylation of alcohols |
| BRPI0418078A8 (pt) * | 2003-12-23 | 2018-01-02 | Astex Therapeutics Ltd | composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto |
| BRPI0622054B8 (pt) * | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| IL295053A (en) * | 2007-03-28 | 2022-09-01 | Pharmacyclics Llc | Broton tyrosine kinase inhibitors |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CN104507946A (zh) * | 2012-07-30 | 2015-04-08 | 康塞特医药品有限公司 | 氘代依鲁替尼 |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
| CN105471823B (zh) * | 2014-09-03 | 2018-10-26 | 阿里巴巴集团控股有限公司 | 一种敏感信息处理方法、装置、服务器及安全判定系统 |
| US10266535B2 (en) * | 2015-01-21 | 2019-04-23 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Inhibitor of FLT3 kinase and use thereof |
-
2016
- 2016-01-13 MA MA041350A patent/MA41350A/fr unknown
- 2016-01-14 JP JP2017532649A patent/JP2018502077A/ja active Pending
- 2016-01-14 HK HK18105861.5A patent/HK1246293A1/zh unknown
- 2016-01-14 MX MX2017009154A patent/MX366827B/es active IP Right Grant
- 2016-01-14 IL IL308276A patent/IL308276A/en unknown
- 2016-01-14 SG SG10201906517VA patent/SG10201906517VA/en unknown
- 2016-01-14 KR KR1020177019206A patent/KR20170102887A/ko not_active Ceased
- 2016-01-14 IL IL322449A patent/IL322449A/en unknown
- 2016-01-14 MX MX2019008815A patent/MX394327B/es unknown
- 2016-01-14 CA CA3210320A patent/CA3210320A1/en active Pending
- 2016-01-14 CN CN202110485400.6A patent/CN113816962A/zh active Pending
- 2016-01-14 EP EP16737886.8A patent/EP3245208A4/en not_active Withdrawn
- 2016-01-14 CA CA2971460A patent/CA2971460C/en active Active
- 2016-01-14 RU RU2017128308A patent/RU2017128308A/ru not_active Application Discontinuation
- 2016-01-14 AU AU2016206693A patent/AU2016206693A1/en not_active Abandoned
- 2016-01-14 WO PCT/US2016/013424 patent/WO2016115356A1/en not_active Ceased
- 2016-01-14 BR BR112017015206-1A patent/BR112017015206B1/pt active IP Right Grant
- 2016-01-14 US US15/542,848 patent/US20180009814A1/en not_active Abandoned
- 2016-01-14 SG SG11201705678YA patent/SG11201705678YA/en unknown
- 2016-01-14 CN CN201680005456.4A patent/CN107108640A/zh active Pending
-
2017
- 2017-06-19 IL IL253020A patent/IL253020A0/en unknown
- 2017-06-26 ZA ZA2017/04338A patent/ZA201704338B/en unknown
-
2018
- 2018-12-18 US US16/224,425 patent/US20190367518A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/703,344 patent/US20200347064A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274716A patent/IL274716A/en unknown
- 2020-09-11 AU AU2020230323A patent/AU2020230323A1/en not_active Abandoned
- 2020-10-09 JP JP2020171454A patent/JP2021035947A/ja active Pending
-
2021
- 2021-02-17 US US17/177,852 patent/US20220098200A1/en not_active Abandoned
-
2023
- 2023-06-14 US US18/209,939 patent/US20240158400A1/en not_active Abandoned
-
2024
- 2024-07-24 US US18/782,878 patent/US20250197404A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246293A1 (zh) | 布鲁顿酪氨酸激酶抑制剂的合成 | |
| BR112015021995A2 (pt) | combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4 | |
| WO2013010136A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| HK1249736A1 (zh) | 布鲁顿氏酪氨酸激酶抑制剂的共结晶体 | |
| IL263815A (en) | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile | |
| ZA201904402B (en) | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease | |
| NZ713828A (en) | Crystalline forms of a bruton’s tyrosine kinase inhibitor | |
| SI3152212T1 (sl) | Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike | |
| HK1215374A1 (zh) | 依鲁替尼联合疗法 | |
| EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
| EP4338738A3 (en) | Pharmaceutical formulations of a bruton's tyrosine kinase inhibtor | |
| MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
| WO2011046964A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| HK1249737A1 (zh) | 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 | |
| EP3601264A4 (en) | BRUTON TYROSINE KINASE INHIBITORS | |
| WO2016066726A3 (en) | Active acrylamides | |
| WO2016032209A3 (ko) | 야누스인산화효소 억제제로서의 치환된 n-(피롤리딘-3-일)-7h-피롤로[2,3-d]피리미딘-4-아민 | |
| EP3988551A4 (en) | CDK KINASE INHIBITOR | |
| EP3912980A4 (en) | CYCLIC MOLECULES AS INHIBITORS OF BRUTON'S TYROSINE KINASE | |
| EP4069689A4 (en) | SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS | |
| HK40072430A (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| HK40069065A (zh) | Jak1选择性激酶抑制剂 | |
| HK40114721A (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
| HK40095190A (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
| HK1260107A1 (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase |